This inventor holds 1 USPTO granted patent. Top assignee: Novartis Ag. Active years: 2003.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2003
Title: Edgar Käslin: Innovator in Transgenic Research
Introduction
Edgar Käslin is a prominent inventor based in Basel, Switzerland. He has made significant contributions to the field of genetic research, particularly in the development of transgenic animals. His work focuses on understanding gene regulation and its implications for medical science.
Latest Patents
Käslin holds a patent for "Transgenic animals for studying regulation of genes." This patent describes a transgenic non-human animal, such as a transgenic mouse, that comprises a polynucleotide encoding a soluble marker protein functionally linked to a regulatory sequence of an endogenous gene encoding E-selectin. The patent also outlines methods for detecting modulators of the E-selectin gene using the transgenic non-human animal and cultured cells derived from it. He has 1 patent to his name.
Career Highlights
Edgar Käslin is associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to explore innovative approaches to gene regulation and its applications in therapeutic settings.
Collaborations
Käslin has collaborated with notable colleagues in his field, including Marcel Luyten and Hans-Günter Zerwes. These collaborations have furthered research in transgenic technology and its potential benefits.
Conclusion
Edgar Käslin's contributions to transgenic research exemplify the intersection of innovation and science. His work continues to influence the understanding of gene regulation and its applications in medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile